3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
608
Pancreatic Neoplasms
371
Carcinoma, Hepatocellular
284
Stomach Neoplasms
236
Rectal Neoplasms
173
Colonic Neoplasms
162
Carcinoma, Non-Small-Cell Lung
160
Esophageal Neoplasms
158
Breast Neoplasms
138
Neoplasms
126
Neoplasm Metastasis
123
Ovarian Neoplasms
114
Lung Neoplasms
104
Cholangiocarcinoma
101
Liver Neoplasms
95
Gastrointestinal Neoplasms
93
Melanoma
82
Biliary Tract Neoplasms
74
Prostatic Neoplasms
71
Esophageal Squamous Cell Carcinoma
66
Endometrial Neoplasms
66
Sarcoma
54
Squamous Cell Carcinoma of Head and Neck
53
Carcinoma, Renal Cell
53
Uterine Cervical Neoplasms
47
Adenocarcinoma Of Esophagus
45
Head and Neck Neoplasms
44
Urinary Bladder Neoplasms
39
Triple Negative Breast Neoplasms
37
Gastrointestinal Stromal Tumors
34
Interventions
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fatty Liver
×
Gastrointestinal
×
90 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled
NCT05692024
2026-05-05
COMMENCER
Massachusetts General Hospital
Phase 1/2
Recruiting
80 enrolled